{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:49:48Z","timestamp":1776106188839,"version":"3.50.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Nasopharyngeal carcinoma is prevalent in Thailand, with a substantial proportion of cases diagnosed at advanced stages. The standard treatment, concurrent chemoradiotherapy, is associated with considerable adverse effects, which may compromise therapeutic efficacy and diminish patients\u2019 quality of life. While vitamin C has shown potential in reducing chemotherapy-induced toxicities in some cancers, its effects in nasopharyngeal carcinoma remain unclear. In this randomized, double-blind, placebo-controlled trial, patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy were assigned to receive either 2 g of intravenous vitamin C or placebo prior to chemotherapy. The incidence of gastrointestinal adverse effects\u2014including nausea, anorexia, mucositis, diarrhea, and dysphagia\u2014did not differ significantly between groups. However, longitudinal analysis demonstrated a significantly attenuated decline in platelet counts in the vitamin C group compared with placebo. Although intravenous vitamin C did not reduce gastrointestinal toxicities, the observed platelet preservation suggests a potential supportive effect that warrants further investigation.<\/jats:p>\n                  <jats:p>Trial registration<\/jats:p>\n                  <jats:p>The study was registered with the Thai Clinical Trial Registry (TCTR20190316003) on March 16, 2019.<\/jats:p>","DOI":"10.1371\/journal.pone.0346818","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:25:53Z","timestamp":1776101153000},"page":"e0346818","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of intravenous vitamin C administration on chemotherapy-induced adverse events in patients with nasopharyngeal cancer"],"prefix":"10.1371","volume":"21","author":[{"given":"Peesit","family":"Leelasawatsuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasawat","family":"Supanimitjaroenporn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattida","family":"Rodsom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theepat","family":"Wongkittithaworn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-3034","authenticated-orcid":true,"given":"Manupol","family":"Tangthongkum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"9476","key":"pone.0346818.ref001","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(05)66698-6","article-title":"Nasopharyngeal carcinoma","volume":"365","author":"WI Wei","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"pone.0346818.ref002","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ajco.12757","article-title":"Epidemiology of head and neck cancer in Thailand","volume":"14","author":"N Tangjaturonrasme","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"issue":"10","key":"pone.0346818.ref003","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1055-9965.EPI-06-0353","article-title":"The enigmatic epidemiology of nasopharyngeal carcinoma","volume":"15","author":"ET Chang","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"pone.0346818.ref004","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2017-0577","article-title":"10-year results of therapeutic ratio by intensity-modulated radiotherapy versus two-dimensional radiotherapy in patients with nasopharyngeal carcinoma","volume":"24","author":"L Chen","year":"2019","journal-title":"Oncologist"},{"key":"pone.0346818.ref005","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.2147\/CMAR.S341472","article-title":"Advanced nasopharyngeal carcinoma: current and emerging treatment options","volume":"14","author":"R Jiromaru","year":"2022","journal-title":"Cancer Manag Res"},{"key":"pone.0346818.ref006","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Plymouth Meeting (PA): NCCN. 2019. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1437"},{"issue":"7","key":"pone.0346818.ref007","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1177\/0300060519858031","article-title":"Toxicities of chemoradiotherapy and radiotherapy in nasopharyngeal carcinoma: an updated meta-analysis","volume":"47","author":"C Wang","year":"2019","journal-title":"J Int Med Res"},{"issue":"3","key":"pone.0346818.ref008","article-title":"Effectiveness and toxicities of intensity-modulated radiation therapy for patients with T4 nasopharyngeal carcinoma","volume":"9","author":"F-F Kong","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"pone.0346818.ref009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13014-021-01929-9","article-title":"Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up","volume":"16","author":"L Wang","year":"2021","journal-title":"Radiat Oncol"},{"issue":"1","key":"pone.0346818.ref010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13046-021-02134-y","article-title":"High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer","volume":"40","author":"F B\u00f6ttger","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"222","key":"pone.0346818.ref011","article-title":"High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy","volume":"6","author":"Y Ma","year":"2014","journal-title":"Sci Transl Med"},{"key":"pone.0346818.ref012","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/antiox7070092","article-title":"Intravenous Vitamin C Administration Improved Blood Cell Counts and Health-Related Quality of Life of Patient with History of Relapsed Acute Myeloid Leukaemia","volume":"7","author":"MN Foster","year":"2018","journal-title":"Antioxidants (Basel)"},{"key":"pone.0346818.ref013","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1479-5876-10-189","article-title":"Effect of high-dose intravenous vitamin C on inflammation in cancer patients","volume":"10","author":"N Mikirova","year":"2012","journal-title":"J Transl Med"},{"issue":"4","key":"pone.0346818.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120228","article-title":"High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial","volume":"10","author":"LJ Hoffer","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0346818.ref015","first-page":"7","article-title":"Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate","volume":"27","author":"J Duconge","year":"2008","journal-title":"P R Health Sci J"},{"issue":"7","key":"pone.0346818.ref016","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C pharmacokinetics: implications for oral and intravenous use","volume":"140","author":"SJ Padayatty","year":"2004","journal-title":"Ann Intern Med"},{"issue":"9","key":"pone.0346818.ref017","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s40262-022-01156-9","article-title":"Up to 100 g of Intravenous Vitamin C Appears to be Safe and Elicits No Adverse Effects but Needs Further Evaluation in High-Risk Groups","volume":"61","author":"PM Honore","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"pone.0346818.ref018","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Bethesda (MD): U.S. Department of Health and Human Services. 2017. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"},{"issue":"19","key":"pone.0346818.ref019","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-22-0655","article-title":"A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX \u00b1 Bevacizumab versus FOLFOX \u00b1 Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)","volume":"28","author":"F Wang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0346818.ref020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/07315724.2005.10719438","article-title":"Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer","volume":"24","author":"AK Pathak","year":"2005","journal-title":"J Am Coll Nutr"},{"issue":"3","key":"pone.0346818.ref021","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/nu13030735","article-title":"High-Dose Vitamin C in Advanced-Stage Cancer Patients","volume":"13","author":"A Zasowska-Nowak","year":"2021","journal-title":"Nutrients"},{"key":"pone.0346818.ref022","first-page":"490804","article-title":"Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis","volume":"2012","author":"M Sultani","year":"2012","journal-title":"Chemother Res Pract"},{"issue":"10","key":"pone.0346818.ref023","article-title":"The Role of Microbiome and Probiotics in Chemo-Radiotherapy-Induced Diarrhea: A Narrative Review of the Current Evidence","volume":"7","author":"S Khorashadizadeh","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"pone.0346818.ref024","doi-asserted-by":"crossref","first-page":"115787","DOI":"10.1016\/j.bcp.2023.115787","article-title":"Chemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management","volume":"216","author":"Y He","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"pone.0346818.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029794","article-title":"Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"7","author":"DA Monti","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"pone.0346818.ref026","first-page":"443","article-title":"Ascorbic acid: chemistry, biology and the treatment of cancer","volume":"1826","author":"J Du","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"pone.0346818.ref027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1549-8719.2010.00080.x","article-title":"Critical role for oxidative stress, platelets, and coagulation in capillary blood flow impairment in sepsis","volume":"18","author":"K Tyml","year":"2011","journal-title":"Microcirculation"},{"issue":"4","key":"pone.0346818.ref028","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1534735414534463","article-title":"Intravenous vitamin C and cancer: a systematic review","volume":"13","author":"H Fritz","year":"2014","journal-title":"Integr Cancer Ther"},{"key":"pone.0346818.ref029","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jcrc.2019.12.011","article-title":"Treating sepsis with vitamin C, thiamine, and hydrocortisone: exploring the quest for the magic elixir","volume":"57","author":"J Obi","year":"2020","journal-title":"J Crit Care"},{"issue":"11","key":"pone.0346818.ref030","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/annonc\/mdn377","article-title":"Phase I clinical trial of i.v. ascorbic acid in advanced malignancy","volume":"19","author":"LJ Hoffer","year":"2008","journal-title":"Ann Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:26:02Z","timestamp":1776101162000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0346818"}},"subtitle":[],"editor":[{"given":"Zhiling","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0346818","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}